Medicine
Maxitrol 1 mg/3.5 mg/10000 units per g eye ointment
Maxitrol 1 mg/3.5 mg/10000 units per g eye ointment is a prescription medicine containing Dexamethasone, Neomycin and Polymyxin b for ophthalmic use, marketed by Sandoz, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 2°C to 25°C (36°F to 77°F).
Key facts
- Active ingredient (INN)
- Dexamethasone, Neomycin and Polymyxin b
- Brand
- Maxitrol
- Strength
- 1 mg/3.5 mg/10000 units per g
- Dosage form
- Eye ointment
- Route
- Ophthalmic
- Packs
- 3.5 g
- Marketing authorisation holder
- Sandoz
- Manufacturers
- SandozNovartis Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 2°C to 25°C (36°F to 77°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.32Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 17 January 1972
- Identifiers
- RxCUI 208601, 309679DailyMed set ID 5776c435-ac60-49b6-8db1-23a3012b9155, 22c6d2db-85af-4a3b-a014-80d901a86717NDC 66758-070, 0078-0771Application NDA050065
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 3.5 g in 1 tube | 66758-070-38 | Sandoz | 2 September 2024 |
| 3.5 g in 1 tube | 0078-0771-01 | Novartis Pharmaceuticals | 25 August 2020 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 6 June 1963 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Dexamethasone, Neomycin and Polymyxin b 1 mg/3.5 mg/10000 units per g eye ointment.
Other strengths and forms of Dexamethasone, Neomycin and Polymyxin b
Clinical summary
Dexamethasone, Neomycin and Polymyxin b is a fixed-dose combination of an aminoglycoside antibacterial, a corticosteroid and a polymyxin-class antibacterial indicated and where bacterial infection or a risk of bacterial infection exists. MedsAcross supplies Dexamethasone, Neomycin and Polymyxin b for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Dexamethasone, Neomycin and Polymyxin bFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- neomycin sulfate, polymyxin b sulfate and dexamethasone prescribing information (Nordic Pharma) · U.S. National Library of Medicine, DailyMed
Need Maxitrol 1 mg/3.5 mg/10000 units per g eye ointment for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.